BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|15|2316-2324

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.15, 2014-08, pp. : 2316-2324

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 675-682

John Wiley & Sons Inc

Access to resources Recommend Favorite

Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis

By  

Oncology, Vol. 91, Iss. 3, 2016-07 ,pp. : 162-170

Karger

Access to resources Recommend Favorite

Improving treatment and survival: a population‐based study of current outcomes after a hepatic resection in patients with metastatic colorectal cancer

By  

HPB, Vol. 17, Iss. 11, 2015-11 ,pp. : 1019-1024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 160-169

John Wiley & Sons Inc

Access to resources Recommend Favorite